Decision Diagnostics Corp.

QUARTERLY REPORT FOR OTC PINK

Supplemental Disclosures

Quarterly Report for Period Ended

March 31, 2016

Trading Symbol: **DECN**
CUSIP Number: **243443 108**

Decision Diagnostics Corp.

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

DECISION DIAGNOSTICS CORP. (11/25/2011-present)
INSTACARE CORP. (through 11/25/2011)

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 2660 TOWNSGATE ROAD
Address 2: SUITE 300
Address 3: WESTLAKE VILLAGE, CA 91361
Phone: 805-446-1973
Email: info@decisiondiagnostics.com
Website(s): www.decisiondiagnostics.com

IR Contact N/A

3) Security Information

Trading Symbol: DECN
Exact title and class of securities outstanding: COMMON
CUSIP: **243443 108**
Par or Stated Value: $0.001
Total shares authorized: 494,995,000 as of: 03/31/2016
Total shares outstanding: 64,622,342 as of: 03/31/2016

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 3,738,500 as of: 03/31/2016
Total shares outstanding: NONE as of: 03/31/2016

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "B"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 2,500 as of: 03/31/2016
Total shares outstanding: 1,000 as of: 03/31/2016

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "C"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 10,000 as of: 03/31/2016
Total shares outstanding: 4,885 as of: 03/31/2016

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "D"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 500 as of: 03/31/2016
Total shares outstanding: NONE as of: 03/31/2016
Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: PREFERRED SERIES "E"
CUSIP: N/A
Par or Stated Value: $0.001
Total shares authorized: 1,750,000 as of: 03/31/2016
Total shares outstanding: 801.840 as of: 03/31/2016

Transfer Agent
Name: ACTION STOCK TRANSFER CORP.
Address 1: 2469 E. FORT UNION BLVD.
Address 2: SUITE 214
Address 3: SALT LAKE CITY, UT 84121
Phone: 801-274-1088
Is the Transfer Agent registered under the Exchange Act?* Yes: XX No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

In April 2015 the company completed voluntary disclosure, periodic financial, and management's discussion and analysis filings (postings) with OTCMarkets, for the purposes of becoming a current voluntary filer. The company's filings were reviewed and the company was granted current filer status with OTCMarkets on April 21, 2015.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

1:14 reverse stock split of $0.001 par value common stock effective 11/25/2011

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

	COMMON STOCK		
Date	Description	Change in Shares	Running Total
12/1/2011	1 for 14 Reverse Split	8,461,032	8,461,032
12/19/2011	New Issuance-Kimberly Binder	75	8,461,107
12/19/2011	New Issuance-Patrick DiParini	200	8,461,307
12/30/2011	10% Stock Dividend	846,669	9,307,976
1/3/2012	DTC Rounding shares	(42)	9,307,934
1/4/2012	New Issuance-Positive Revolution Inc-S-8	100,000	9,407,934
1/11/2012	Converted to Common-Alpha Credit	294,000	9,701,934
1/18/2012	New Issuance-Debt Conv. Andrew Edenbaum	53,354	9,755,288
1/23/2012	DTC Rounding shares	25	9,755,313
3/5/2012	New Issuance-JFS Investments Inc	60,000	9,815,313
3/5/2012	New Issuance-Garden State Securities	60,000	9,875,313
3/5/2012	New Issuance-Excell Advisors	30,000	9,905,313
3/5/2012	Return to Treasury-Positive Revolution	(100,000)	9,805,313
3/5/2012	New Issuance-TPC Holdings Group-ESOP-06	300,000	10,105,313
3/5/2012	New Issuance-Cadence Consulting-ESOP-06	50,000	10,155,313
3/30/2012	New Issuance-Alpha Credit Resources	238	10,155,551
6/27/2012	New Issuance-Rocio C Carazas-ESOP-06	375,000	10,530,551
6/27/2012	New Issuance-Marjolein Imfeld-ESOP-06	375,000	10,905,551
9/26/2012	Converted to Common-Centurion	172,200	11,077,751
10/9/2012	New Issuance-Aubyn Inc-ESOP-06	400,000	11,477,751
11/8/2012	Return to Treasury-Aubyn Inc-ESOP-06	(200,000)	11,277,751
11/8/2012	New Issuance-Mayer & Assoc. Esop-04	650,000	11,927,751
11/8/2012	New Issuance-Mayer & Associates	200,000	12,127,751
11/8/2012	New Issuance-Curing Capital Inc	400,000	12,527,751
11/13/2012	Converted to Common-Centurion	182,000	12,709,751
11/13/2012	New Issuance-Econ Corporate Services	50,000	12,759,751
11/13/2012	New Issuance-Call Van Zant-ESOP-06	100,000	12,859,751
11/13/2012	New Issuance-Darren Bankstead-ESOP-06	50,000	12,909,751
11/13/2012	New Issuance-Axiom Financial Inc	200,000	13,109,751
12/21/2012	Cancellation-Mayer & Associates LLC	(200,000)	12,909,751
12/21/2012	New Issuance-Mayer & Associates LLC	1,000,000	13,909,751
1/7/2013	New Issuance-Mayer & Associates LLC	50,000	13,959,751
1/7/2013	Converted to Common-Apex Clearing	210,000	14,169,751
1/7/2013	Converted to Common-Apex Clearing	236,600	14,406,351
2/15/2013	New Issuance-TPC Holdings Group-ESOP	1,325,000	15,731,351
2/15/2013	New Issuance-Envisionte LLC-ESOP	700,000	16,431,351

2/15/2013	New Issuance-Bridgeview Capital Group ESOP	700,000	17,131,351
2/15/2013	New Issuance-Cadence Holdings LLC ESOP	275,000	17,406,351
2/15/2013	New Issuance-AAC Group LLC ESOP	600,000	18,006,351
2/15/2013	New Issuance-Cadence Holdings LLC ESOP	150,000	18,156,351
2/15/2013	New Issuance-St Andrews Inc	1,000,000	19,156,351
2/15/2013	New Issuance-Alan Binder ESOP	100,000	19,256,351
2/15/2013	New Issuance-Dale Richter ESOP	100,000	19,356,351
2/15/2013	New Issuance-Kimberly Binder ESOP	50,000	19,406,351
2/15/2013	New Issuance-Maria Luz Johnson-ESOP	25,000	19,431,351
2/18/2013	Converted to Common-Apex Clearing	324,800	19,756,151
2/22/2013	New Issuance-Robert Herskowitz ESOP	500,000	20,256,151
2/22/2013	New Issuance-Jeff Whitelaw	125,000	20,381,151
2/22/2013	New Issuance-Brent England	75,000	20,456,151
5/9/2013	Converted to Common-Apex Clearing	868,000	21,324,151
5/10/2013	Cancellation-Robert Herskowitz ESOP	(500,000)	20,824,151
5/10/2013	Cancellation-St. Andrews	(1,000,000)	19,824,151
5/10/2013	New Issuance-Chase Financing Inc ESOP	350,000	20,174,151
5/10/2013	New Issuance-Mayer & Associates LLC ESOP	1,000,000	21,174,151
8/7/2013	New Issuance-St Andrews Inc ESOP	500,000	21,674,151
8/15/2013	New Issuance-Robert Herskowitz ESOP	25,000	21,699,151
8/27/2013	Cancellation-Curring Capital	(200,000)	21,499,151
8/27/2013	Cancellation-ACC Group ESOP	(600,000)	20,899,151
8/27/2013	New Issuance-Benjamin Mayer ESOP	950,000	21,849,151
9/20/2013	New Issuance-SLCC Partners LLC	1,000,000	22,849,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	500,000	23,349,151
9/20/2013	New Issuance-Thomas Hanson-ESOP	250,000	23,599,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	250,000	23,849,151
10/2/2013	New Issuance-Joanne Broeders-ESOP	235,300	24,084,451
10/2/2013	Cancellation-Alan Binder ESOP	(100,000)	23,984,451
10/2/2013	New Issuance-Kimberly Binder	100,000	24,084,451
10/2/2013	Converted to Common-COR Clearing	1,078,000	25,162,451
10/28/2013	Converted to Common-Michael Belcher	350,000	25,512,451
10/28/2013	New Issuance	2,798,728	28,311,179
10/30/2013	New Issuance-Benjamin Mayer ESOP	100,000	28,411,179
10/30/2013	New Issuance-Benjamin Mayer	300,000	28,711,179
10/30/2013	New Issuance	166,365	28,877,544
11/11/2013	Conversion-Centurion Credit	980,000	29,857,544
11/11/2013	New Issuance-Benjamin Mayer ESOP	500,000	30,357,544
11/11/2013	New Issuance	125,000	30,482,544
12/4/2013	Conversion-Centurion Credit	1,220,800	31,703,344
12/23/2013	New Issuance-Mark Herskowitz ESOP	175,000	31,878,344
12/23/2013	New Issuance-Benjamin Mayer ESOP	600,000	32,478,344
12/23/2013	New Issuance	1,200,548	33,678,892
1/2/2014	New Issuance	2,709,678	36,388,570
1/15/2014	New Issuance	748,720	37,137,290
1/15/2014	New Issuance	267,105	37,404,395
2/18/2014	Conversion-Alpha Credit	611,940	38,016,335
2/18/2014	Conversion-Michael Belcher	350,000	38,366,335
2/19/2014	Conversion-Mayer & Associates	798,000	39,164,335

3/28/2014	Conversion-Alpha Credit	523,740	39,688,075
3/28/2014	New Issuance	400,000	40,088,075
6/3/2014	Conversion-Alpha Credit	499,996	40,588,071
6/4/2014	Conversion-Mayer & Associates	1,115,660	41,703,731
8/14/2014	Conversion-Alpha Credit	245,000	41,948,731
8/15/2014	Conversion-Mayer & Associates	550,000	42,498,731
9/9/2014	Conversion-Mayer & Associates	775,000	43,273,731
10/28/2014	Conversion	675,010	43,948,741
1/21/2015	New Issuance	1,875,000	45,823,741
1/28/2015	New Issuance	850,000	46,673,741
2/23/2015	Conversion-Alpha Credit	705,124	47,378,865
5/11/2015	New Issuance-Momona Capital	235,000	47,613,865
5/12/2015	Conversion-Mayer & Associates	950,040	48,563,905
5/12/2015	New Issuance-Robert Herskowiz	950,000	49,513,905
5/21/2015	New Issuance-Momona Capital	235,000	49,748,905
6/1/2015	New Issuance-Chase Financing 401K	533,334	50,282,239
6/8/2015	New Issuance-Momona Capital	437,250	50,719,489
6/8/2015	New Issuance-St Andrews	350,000	51,069,489
6/29/2015	New Issuance-Alpha Capital Anstalt	384,537	51,454,026
7/27/2015	New Issuance-Alpha Capital Anstalt	387,907	51,841,933
8/24/2015	New Issuance-Alpha Capital Anstalt	313,022	52,154,955
9/16/2015	Conversion-Mayer & Associates	1,890,000	54,044,955
9/16/2015	Conversion-Robert Herskowitz	1,400,000	55,444,955
10/27/2015	New Issuance-Alpha Capital Anstalt	479,489	55,924,444
12/2/2015	New Issuance-Alpha Capital Anstalt	950,545	56,874,989
12/15/2015	New Issuance-Alpha Capital Anstalt	950,545	57,825,534
12/21/2015	New Issuance-Alpha Capital Anstalt	956,950	58,782,484
2/2/2016	New Issuance-Alpha Capital Anstalt	970,980	59,753,464
2/17/2016	New Issuance-Alpha Capital Anstalt	1,614,248	61,367,712
2/25/2016	New Issuance-Robert Herskowiz	750,000	62,117,712
3/21/2016	New Issuance-Paradigm Capital Holdings	1,400,000	63,517,712
3/21/2016	New Issuance-Robert Herskowitz	200,000	63,717,712
3/29/2016	New Issuance-Alpha Capital Anstalt	404,630	64,122,342
3/29/2016	New Issuance-James J Loures	500,000	64,622,342

PREFERRED B STOCK

Date	Description	Change in Shares	Running Total
3/23/2011	New Issuance-Centurion Credit Resources	1,000	1,000

PREFERRED C STOCK

Date	Description	Change in Shares	Running Total
1/4/2012	New Issuance-Michael Belcher	1,250	1,250
8/27/2013	New Issuance-Lathrop Gage LLC	1,500	2,750
10/28/2013	Conversion-Michael Belcher	(70)	2,680
2/18/2014	Conversion-Michael Belcher	(70)	2,610
12/30/2015	New Issuance-Navesink Device Initiatives	1,475	4,085
3/21/2016	New Issuance-Paradigm Capital	800	4,885

PREFERRED E STOCK

Date	Description	Change in Shares	Running Total
5/17/2011	New Issuance-Centurion Credit	135,000	1,095,300
1/11/2012	Converted to Common	(21,000)	1,074,300
3/30/2012	New Issuance-Alpha Credit Resources	124,700	1,199,000
9/26/2012	Converted to Common	(12,300)	1,186,700
11/13/2012	Converted to Common	(13,000)	1,173,700
1/7/2013	Converted to Common	(15,000)	1,158,700
1/7/2013	Converted to Common	(16,900)	1,141,800
2/18/2013	Converted to Common	(23,200)	1,118,600
5/9/2013	Converted to Common	(62,000)	1,056,600
10/2/2013	Converted to Common	(77,000)	979,600
11/11/2013	Conversion-Centurion Credit	(70,000)	909,600
12/4/2013	Conversion-Centurion Credit	(87,200)	822,400
1/15/2014	Conversion-Alpha Credit	(53,480)	768,920
2/18/2014	New Issuance-Mayer & Associates	125,000	893,920
2/18/2014	Conversion-Alpha Credit	(43,710)	850,210
2/19/2014	Conversion-Mayer & Associates	(57,000)	793,210
3/28/2014	Conversion-Alpha Credit	(37,400)	755,810
6/3/2014	Conversion-Alpha Credit	(35,714)	720,096
6/4/2014	Conversion-Mayer & Associates	(79,690)	640,406
8/14/2014	Conversion-Alpha Credit	(17,500)	622,906
8/15/2014	Conversion-Mayer & Associates	(39,285)	583,621
9/9/2014	Conversion-Mayer & Associates	(55,357)	528,264
10/28/2014	Conversion-Mayer & Associates	(30,358)	497,906
1/21/2015	New Issuance-Robert Herskowitz	100,000	597,906
1/21/2015	New Issuance-Mayer & Associates	135,000	732,906
1/21/2015	New Issuance-Alpha Credit Resources	67,860	800,766
2/23/2015	New Issuance-Alpha Credit Resources	(50,366)	750,400
5/12/2015	Conversion-Mayer & Associates	(67,860)	682,540
5/12/2015	New Issuance-Robert Herskowitz	30,000	712,540
7/27/2015	New Issuance-Chase Financing	75,000	787,540
9/16/2015	Conversion-Mayer & Associates	(135,000)	652,540
9/16/2015	Conversion-Robert Herskowitz	(100,000)	552,540
9/16/2015	New Issuance-Chase Financing	135,000	687,540
2/25/2016	New Issuance-Robert Herskowitz	100,000	787,540
3/21/2016	New Issuance-Mayer & Associates	14,300	801,840

A. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

See above

5) Financial Statements

SEE FINANCIAL STATEMENTS ATTACHED TO THIS DISCLOSURE STATEMENT

6) Describe the Issuer's Business, Products and Services

Overview

Decision Diagnostics Corp. is a nationwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of the Genstrip 50 and GenUltimate! glucose test strips, class II medical devices for at-home use for the measurement of glucose. The U.S. FDA, in a manner similar to prescription drugs, regulates diagnostic test kits and at-home patient testing products similarly to the regulation of prescription medicine. The regulatory standard used for the Genstrip 50 and the later GenUltimate! was the 510k process. Both products make use of the same FDA 510k clearance (GenUltimate! is a trade name and registered Trademark of Pharma Tech Solutions, Inc.). The company has, since 2005 and until 2013, contracted with independent pharmacies for use of their prescription drug distribution licenses. However, the products we currently distribute, for the most part, do not require a doctor's prescription for anything other than insurance benefit compliance. Our business model works well in this regulated environment, although the financial benefits are now limited by major changes made to the Medicare plan that have lead to substantially lower rates of reimbursement.

Our subsidiaries, Pharma Tech Solutions, Inc. and PDA Services, Inc. operate in several healthcare products distribution channels. In addition our subsidiary Decision IT Corp. engages in the acquisition and holding of Intellectual Property including Patents and Trademarks. Our new subsidiary PharmaTech Sensor Development Corp. was incorporated to work with our Korean partner and manage an inventory credit line. From time to time, when economic conditions warrant and and given market conditions, we distribute brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound care and post-surgery medical products, although these healthcare channels have also undergone market changes since July 2013 and we have determined that we will maintain our contacts and agreements but will refrain from competing. Our main product is the Genstrip 50 (and GenUltimate!), a slight rebranding of the original Shasta Technologies Genstrip, cleared for market on November 30, 2012. By virtue of our our written agreements with Shasta, we were granted an irrevocable license to prosecute their 510k application with the U.S. FDA, and succeeded. We introduced Genstrip in March 2013. We acquired Genstrip from Shasta Technologies LLC on March 20, 2014 and in late June 2014 we began the minor branding changes. Shasta Technologies had a long-standing difficult relationship with the U.S. FDA and was the subject of a worldwide Safety Notice on April 29, 2014, effectively ending Shasta's ability to be a player, due to irreparable regulatory deficiency in the highly regulated medical device industry. The company's acquisition of Genstrip (now Genstrip 50 and /gen/ultimate!) was fortuitous given the finality and outcome of Shasta Technologies' troubles with the FDA.

The U.S. FDA cleared the Shasta Genstrip product for sale in the U.S. on November 30, 2012. The worldwide market for at-home blood glucose testing is an estimated $22.5 billion. Genstrip50 (and GenUltimate!) compete directly with one of the largest worldwide platform manufacturer for at-home blood glucose testing, a product currently used daily by over 3 million diabetes afflicted Americans. In addition, since the medical device employed by this legacy platform manufacturers, Genstrip50 (and GenUltimate!) also compete in the overall at-home testing market by offering an economical solution to former users of the legacy platform providers product. In that regard, Genstrip50 (and GenUltimate!) are unique as our major business focus is directed toward diabetics who have attempted a change of glucose monitoring platforms (systems) or those currently using the legacy products but are dealing with escalating prices and lower insurance reimbursements.

Throughout 2012 in anticipation of the introduction of Genstrip and finally Genstrip50 (and GenUltimate!), we evaluated our brand-name distribution model, a model that provided streams of revenue but extremely low profit margins, and over the course of the last 30 months we have phased out sales of those brand name products that had been a backbone of our distribution business. In addition the brand name products distribution business created a situation where we were selling products that competed directly with our own Genstrip 50. Phasing out these brand name products lowered our order intake by approximately $4,850,000 in the first two quarters of 2016 but allowed us to become a manufacturer and product specifications design agent, at a much higher level in the large market channel.

The company will continue to direct its marketing efforts to ambulatory and semi-ambulatory older Americans afflicted with diabetes and complications caused by diabetes and old age. The company, originally a medical IT company with proprietary IT product lines, acquired its medical products distribution business in late 2004 through a merger with Phoenix, Arizona based CareGeneration, Inc. We have grown the original CareGeneration business through subsequent acquisitions of private businesses and strategic partnerships with larger private pharmacies and finally to manufacturing our own Class II medical device products.

On November 1, 2011 we completed the acquisition of Diagnostic Newco LLC from its owner Kimberly Binder. Diagnostic Newco LLC is a design company that specializes in product packaging design, medical products advertising design and graphic art. Ms. Binder has joined the staff of the company's Pharma Tech Solutions, Inc. subsidiary specifically for these purposes, and has worked closely with the contract manufacturers for Genstrip 50 and GenUltimate!, making subtle changes to packaging design among other responsibilities. She will also be responsible for the package design for new diagnostic products the company is currently working on. Ms. Binder is also owner of GenstripDirect, LLC and Full Circle Diabetes LLC, her own distribution companies, separate from her company related responsibilities. Ms. Binder is also the Company's designated agent for FDA matters.

We also intend to acquire additional private companies, focusing on small engineering companies that have developed technology requiring either regulatory approval, distribution or both. In December 2011 we made another small acquisition, to acquire the services of Mr. Patrick Deparini. We are moving quickly to achieve our goal of becoming a vertically integrated, full service value added provider of products and services to an ever-growing market. The at-home diabetes testing market continues to grow as diabetics continue to be diagnosed.

The company's current proprietary product offering, cleared by the FDA for commercial distribution on November 30, 2012, is the Genstrip50 (and GenUltimate!) blood glucose diagnostic test strip for at-home testing. Genstrip is a product originally conceived by Shasta Technologies LLC, and acquired by our Pharma Tech subsidiary on March 20, 2014, fits into a diagnostic product niche and will sell into the world-wide self-test (home test) market that is expected to grow to $32 billion worldwide by 2017. Since Genstrip 50 is a rather unique offering, employing a brand name razor blade only model (diagnostic test strip) into a razor (diagnostic meter)--razor blade (diagnostic test strip) market, the Genstrip 510(k) application presented some unusual challenges for the FDA and an educational challenge and opportunity for the company. Since the company plans additional similar products in the future for other diagnostic platforms, and in fact has contracted with our Korean partner to develop two such parallel products, the "Genstrip" experience, however slow and unresponsive it was, has provided lessons and experience.

Two years (and growing) is a standard development to market timeline for in-vitro diagnostic products similar to Genstrip50 (and GenUltimate!). As a result of previous delays by Shasta Technologies in completing its FDA approval application [510(k)] and then problems Shasta encountered in prosecuting its original application with FDA staff, the company changed its contractual responsibilities and obligations in June 2011 to include program management, regulatory process management, management of the manufacturing forecasting and distribution processes, and new products planning and development. Further on-going problems encountered by Shasta, which on their face appeared irresolvable, presented the company with an opportunity. On March 20, 2014 our Pharma Tech Solutions, Inc. subsidiary acquired the intellectual property, the marks, and the GenStrip cleared 510(k).

In June 2010 the company was approached by the largest retailer in the world for the distribution and sale of the Genstrip product,then about to enter the 510k regulatory process, at over 5,000 retail stores worldwide. A contract with this retailer was negotiated in September 2010 and subsequently renegotiated and renewed in April 2011, and as soon as the retail contract was agreed to and as a means to conduct market research, the company began seeking pre-conditioned letters of intent (pre-orders) for Genstrip, while continuing the prosecution of the 510(k) application on behalf of Shasta Technologies before the FDA. Discussions with this retailer and other similarly situated retailers have been on a litigation induced hiatus since our litigation with Lifescan, Inc. began in earnest in late March 2013. Lifescan Inc. is a division of Johnson & Johnson. This litigation was finally brought to a merciful end on April 28, 2016. There are no victors in complex litigation although in the three cases we settled with Johnson & Johnson, we were paid a healthy sum to drop our counter-claims against Johnson & Johnson.

Currently that market is dominated by four large pharmaceutical manufacturers who provide very similar and equally focused products, selling at essentially equal prices. Genstrip50 (and GenUltimate!) introduction, even with the fits and starts, will not only allow the company to achieve market share but because of the business model to be employed by Genstrip50 (and GenUltimate!) is different than those models employed by the major market players, the company may be able to change the market, lowering average price or allowing for increased testing by diabetics for a lesser price, thereby affecting all market segments. The company's major market focus is to pharmacy chains, grocery chains with in-store pharmacies, large all purpose retailers with in-store pharmacies, and group buying and chain pharmacy organizations. In the recent past our model might have been called a private label model or a value added model, but with the advent of the July 2013 changes to Medicare (and followed by private insurers), pharmacy business models are now blurred.

We also offer information technology solutions in several medical care market channels by providing physicians with information at the point of care. Our products, unlike those from many other medical information companies, make use of smart cell phones such as the Apple iPhone, the Palm Pre, the Google Droid and a wide selection of Microsoft Windows based smart phones and operate in either in a wireless or "wired" mode, which allow physicians to carry, access and update their patients' histories, also known as electronic medical records or EMR, medication data, and best care guidelines - *all at the point of care*, or from any other location the physician may be located. In addition, the company's products employ proprietary mathematical game theory features adapted by the company for medical use that allow acceptance of diagnoses and treatment protocols where the medical information may have originated from one or several locations and one time or several times.

In October 2014 we adopted a value added/private label business model to address the issues brought to our market by the radical reimbursement changes by the federal Medicare program. We also hired a market executive with over 40 years of experience to implement our new strategy. In April 2016 we signed a wide reaching agreement with Bentonville, AR based Retail Monster LLC. "Monster" is going to represent the Company in 17 "A" list retailers in the U.S. and Canada.

In March 2016 we acquired special intellectual property which shall serve our business interests now and into the future. We finalized an arrangement with Alpha Capital Anstalt ("Alpha") on during 1st quarter March 31, 2016 whereby Alpha purchased an 18-month 15% OID derivative instrument in the amount of $275,000 from the company to facilitate the acquisition of this intellectual property. Terms of this agreement with Alpha call for a 15% OID with both redemption and conversion features and 50% Warrant coverage (for follow-on investment). The conversion feature set the conversion price as the closing price of the company's common stock on March 27, 2015 less $.02 per share. We completed another transaction with Alpha in June 2015 under similar terms to the March 2015 transaction. On the most recent transaction Alpha financed our acquisition of specialty manufacturing equipment to facilitate our contract manufacturer in Korea. In addition we accepted a derivative subscription from Alpha in December 2015 and a credit line derivative subscription in April 2016. These latest subscriptions total $1.15 million.

In the Fall of 2014 the company announced its Discretion cloud wireless glucose monitoring product concepts, which will be manufactured for the company according to spec by its Korean contract manufacturer. In April 2015 the company entered into discussions with HMD Biomedical, Inc. in Taiwan for the importing of HMD's FDA cleared "Cloudia," product. In January 2015 the Company suspended working on this product until the Cloudia product was made easier to use by a diabetic. We eagerly await this generation 2 Cloudia. The company has also adapted its smart cell-phone medical software, an outgrowth of the company's MD@Hand development, so that users can monitor and track their diabetes treatment and monitoring on their smart cell phones. This software will also be adapted for future users of its internally developed Discretion product.

We have received multiple inquiries from companies interested in perhaps collaborating with the company for the implementation of its cell phone centric technologies MD@Hand and MD@Work. However, the market available for products similar to MD@Hand and MD@Work has changed since its introduction in 2009. The legal challenges to the new health care law and the federal government's inability to enact regulations have altered the landscape, again. We remain in discussions with multiple concerns for the marketing of our MD@ products, and any agreement we may enter will require us to provide contract software programming, providing a new source of revenue for the company. In addition to any proposed partnerships, we continue to discuss alternative propositions with other interested companies ranging from clinical laboratories, service organizations owned or aligned with medical health insurers, a medical content provider and legacy healthcare systems companies. There remains sustained interest in our MD@ technology. All of our discussions are with companies are much larger than Decision Diagnostics. We may or may not entertain additional proposed partnerships for our implementation of the cell phone centric technologies, which has been hindered, as has the overall market, by the slow implementation of regulations, protocols and data formats by the Federal government, as well as a change in previously announced Federal government monetary incentives.

In May 2010, we entered into agreement with Shasta Technologies, Inc. and Broadtree, Inc. This agreement granted our Pharma Tech Solutions, Inc. subsidiary the exclusive marketing rights to a new diagnostic product not yet on the market named Shasta Genstrip ("Genstrip"). The Genstrip product was developed to compete against the market leader in the $20 billion at home testing market. Shasta was in default of this 2010 Agreement, and owed the company in excess of $2 million in "delay" penalties, which they were unable to pay, so in April 2011, the company renegotiated its agreement changing its many roles and adding responsibility for regulatory approval, manufacturing and forecasting, international sales and additional sales markets in the U.S. On March 20, 2014 we acquired the GenStrip intellectual property, its marks and the cleared 510(k). On April 30, 2014 we first implemented our FDA mandated Quality Plan and are now operating as the manufacturer (operator) of the GenStrip 50.

We currently employ five professionals at our executive business office located at 2660 Townsgate Road, Suite 300, Westlake Village, California 91361. In addition, we maintain two full-time and seven part-time positions located throughout the United States. We also maintain a Quality Assurance office in York, PA as a means to fulfill our quality commitment to the FDA. This office is staffed by our Principal Executive who commutes several times monthly (especially during manufacturing runs) from California. We also maintain a new Quality Assurance office at our California facility to fulfill our FDA commitment for Korean manufactured products. Our telephone number is (805) 446-1973 and our website addresses arewww.decisiondiagnostics.com and www.pharmatechdirect.com.

The company's stock currently trades on the OTCMarkets OTC Pink Current tier of the market. The company's shares are DTC eligible. On May 12, 2015 the company made an application for a tier change to the OTCQX (common) tier. The company's application is currently being supplemented to meet several recent SEC penny stock rules, and the company has received a proposed solution for the penny stock rules issue from OTCMarkets, but more importantly the company's sponsoring brokerage unexpectedly and without notice voluntarily shut down as of May 31, 2015. Thus, we are seeking a new sponsoring relationship. Prior to the shutdown of this brokerage, the company did secure the approval of its Designated Advisor for Disclosure (DAD), a mandated part of the process.

Business activities throughout the next twelve months:

The company's business on a day-to-day basis (in 2016) includes the distribution of our GenStrip 50 and GenUltimate! test strips, and the distribution of prescription and non-prescription diagnostics, at-home testing, post-surgical products.

Beginning in November 2009, we introduced our cell-phone centric medical IT products that offer solutions in medical care and management by providing physicians with information at the point of care. Unlike other medical information systems using standard computer terminals or even palm-sized computers (PDA's), our software applications operate on a series of late generation smart e-cell phones including the Apple iPhone, the Palm Pre, the Google Droid, several makes of RIM's Blackberry and many versions of the Microsoft Windows smart phones. Our products allow physicians to access and update their patients' histories, medication data, and best care guidelines - *all at the point of care*. The company's Electronic Medical Records software is believed to be the first EMR application running on any palm sized mobile device. Recently we ported our software to run on a series of pad computers such as Apple iPad and the 'Droid powered pads.

Our business objectives include:

1. The practice of specializing in the distribution of Genstrip 50 and GenUltimate, and in the several brand-name medical diagnostic and medical disposable products associated with the on-going care of diabetes-inflicted patients, and the world-wide distribution of our proprietary diagnostic product GenUltimate!.
2. Combining our wholesale and retail drug distribution with our cell phone centric technologies, creating wholesale and retail ePharmacies similar in function to existing Internet pharmacies but directed to serving the large base of underinsured and uninsured Americans; and
3. Providing medical communication and EMR medical history and storage devices based on networks of smart cell phones These products are believed to provide benefits of on demand medical information to private practice physicians, licensed medical service providers such as diagnostic testing laboratories, and medical insurers. We have created cell phone-centric products and a suite of Internet enhanced software applications that include those features that specifically respond to the requirements of the practicing physician and the regulations currently being promulgated by the Federal government.

We also have adapted our medical communications and EMR technologies to service the real estate management and hotel/motel/convenience industries in their own commercial settings. In March 2010, our Board approved the sale of the company's hotel/motel technologies and business base so we can focus on our core medical IT and medical distribution businesses. In past years when we had market focus on the hotel/motel industry, our real estate and hotel/motel objectives include building electronic commerce networks based on personal digital assistants (PDA) and pad based computers to the hotels, motels and single building, multi-unit apartment buildings with a desire to offer local advertising and electronic services to their tenants/guests.

As a part of the company's strategic plans, we have applied (to register) for seven Trademarks with the USPTO. The company's Genstrip product is a registered Trademark of Shasta Technologies LLC. Our applications were filed with the USPTO in 1Q and 2Q 2015. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and the establishment of a family of Marks associated with our company and its place in our industry. As of November 16, 2015 the company has received registration confirmation from the USPTO for the following Marks:

"Alltara!"
"GenUltimate!"
"Discretion Messenger"
"ValuStrips"

During the 4th Quarter 2015 and first Quarter 2016 the company suffered severe inventory shortage of the Genstrip 50 product at various times, owing to the timing of the various settlements with Johnson & Johnson. For some period of time the company's contract manufacturer was unable, due to their settlement with Johnson & Johnson, to ship to the company certain quantities of the Genstrip product. This problem began to clear up in late March 2016, and with the advent of adding the GenUltimate! product from Korea, shortages have been alleviated. The company's capacity for Genstrip 50 and GenUltimate! production is now 500,000 packages per month (50 strips per package).

Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our GenStrip 50 and GenUltimate! products required initial regulatory approval by the USFDA as well as on-going USFDA approvals during the product life cycle. Further, these products required medical patient trials and competes directly with a major platform manufacturer.

Healthcare, especially those segments where the company competes, is a very litigious. Competing companies often use litigation as a marketing tool, bringing litigation as a means to protect market share and limit market exposure. We have in the past (and currently) defended cases brought by Plaintiffs asserting these types of claims.

The medical industry is also intertwined. From time to time, we may become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, litigation that arises over payment disputes or claims of fair value. We have defended cases of this nature. Often these cases spin out of control. For instance we have been sued in several jurisdictions that involved the same or a single business transaction. Often these cases involve substantial over-prosecution where the company and its directors have been held accountable by Plaintiffs for things said or written in public by anonymous persons.

We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers, people or entities that we not be familiar with. The company maintains substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. The company has also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, the company accrues contingent legal fees and product liability fees. As of December 31, 2015, our accrual was $245,069.

From time to time, the company may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered material or potentially material to us.

Johnson & Johnson, Lifescan, Inc. and Lifescan Scotland Ltd.

We have been in litigation with Lifescan Inc. a subsidiary of Johnson & Johnson since September 2011. Lifescan has maintained throughout that our Genstrip product infringes on three of their patents. One of these patents has become the subject of peripheral litigation activities, and three Appeals to the U.S. Appeals Court for the Federal Circuit (the

patents appeals court). Throughout this Appeal process, and a litigation process waged through the USPTO, the company has prevailed. Recently, as a result of certain claims and allegations made by Lifescan after the close of the USPTO final determination (in favor of the company), the office of the Solicitor General has intervened against Lifescan Inc. in the Federal Circuit court. In January 2016 the Federal Circuit court ruled against Lifescan/J&J by issuing a Rule 36 pronouncement, a ruling without written analysis, a tool typically used when the court finds that the appellant's argument is without merit. Lifescan/J&J has indicated that they intend to file for a rehearing no later than April 6.

The seeming baseless allegations and claims made by Lifescan against the company have taken their toll, limited our ability to sell Genstrip 50 (and GenUltimate!) to large entities ("big box stores") and greatly extended the court processes. In factthe office of the solicitor, in written pleadings, accused Lifescan/J&J of "sandbagging."

In the Spring of 2013, fearing the impact of the Genstrip product in an open market, Lifescan took it upon themselves to violate a court protective order and prepared and sent out thirty page certified (veiled threat) letters to customers of the company and the customers of the company's customers, making it clear to these entities that should they do business with the company, or buy Genstrip product from others doing business with the company, they could or would be added as defendants to the patent infringement suit. Most independent pharmacies in the U.S. sell less than a case (24 boxes) of a single brand of glucose test strips monthly. It is easy to ascertain that an independent pharmacy would choose not to "poke the bear" and risk a several hundred thousand dollar defense, rather than halting sales of Genstrip. Some large retailers were visited or called by Lifescan management and provided with the same veiled threats. Lifescan even calculated that by breaching the protective order, the sanctions they would be assessed would amount to far less than the business loss they would otherwise suffer. Slowly however, the litigation environment enjoyed by Lifescan has changed.

In the spring of 2015, Lifescan, perhaps realizing litigation reality, dismissed all of their claims involving one patent, with prejudice, and dropped (with prejudice) all damage claims on a second of their three patents. Two of Lifescan/J&J's patents have now expired and the litigation surrounding them has moved into a dueling court Motion exercise. The third Lifescan patent, the foundation patent for their OneTouch Ultra product, is clinging to life in an appeals court, with the office of the Solicitor General intervention, that patent was terminated in USPTO court hearings and appeals, because this patent contained unpatentable technology and patent claims.

More recently, during the writing of this document, the company has requested again, all documents related to communication with these besieged customers of the company, and the customers of the company's customers. Certified mail leaves an audit trail, and soon through the court discovery process for a $12.7 million court bond surety, the company will be able to get to the bottom of this illegal behavior. Proving this behavior would help the prospects of Genstrip 50 and GenUltimate! dramatically.

In December 2014 counsel for Lifescan wrote a letter to the trial judge who is hearing all three patent matters. This letter outlined a series of issues involving Lifescan's lead damages "expert" during litigation proceedings. Lifescan's expert claimed educational and qualification credentials that were not true at the time of the "expert" testimony, and are not true even today. This expert also assisted Lifescan's counsel in at least one other case, and other companies' counsels in unrelated cases. Testimony from this expert, in each instance, allowed the Plaintiffs in these cases to secure court rulings to the detriment of the Defendants. In the company's case this expert was used twice and assisted Lifescan to receive preferential treatment from the court for setting of a litigation bond to cover potential damages, wherein the "expert" through testimony limited the scope and calculation of damages in the setting of the damages protection afforded by the litigation bond and the damages resulting from Lifescan's violation of the court protective order. Lifescan's letter admonition came over a year after their successful use of this "expert."

In late March 2016 the Company filed a patent infringement suit in the District Court of Nevada against Johnson + Johnson and several divisions. This suit is separate from the collection of suits that were heard in San Franciaso, CA.

On May 9, 2016 the U.S. Court of Appeals for the Federal Circuit ruled against Lifescan's appeal for a re-hearing and an en banc hearing. A Mandate from the court will issue on May 17, 2016. Lifescan's '105 patent, the foundation for so much of this litigation was revoked.

Certain of the three cases in front of the trial judge in the Federal District court, have most recently been ordered to mediation for the third time, as the disposition of these cases nears conclusion. On April 28, 2016 the mediation took place and was successful. The trial judge filed an "end of cases" ruling on April 29, 2016.

A. Date and State (or Jurisdiction) of Incorporation:

INCORPORATED IN THE STATE OF NEVADA ON MARCH 2, 2001 AS ATR SEARCH CORPORATION

B. the issuer's primary and secondary SIC Codes;

5122, 7371

C. the issuer's fiscal year end date;

DECEMBER 31

D. principal products or services, and their markets;

Genstrip 50 Glucose Test Strips and GenUltimate! Glucose Test Strips for use with Johnson & Johnson Lifescan glucometers. MD@Hand medical communication and EMR software for use with smart cell phones.

7) Describe the Issuer's Facilities

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is $2,170 per month on a month-to-month basis. Our Pharma Tech subsidiary maintains a facility for quality assurance and control of its FDA QSR at 750 Borom Road, York, PA

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Our executive officers, directors, and key employees are:

Name	Age	Position

Keith Berman	62	Chief Financial Officer and Director
William Lyons	62	Director
Robert Jagunich	68	Director

Our shareholders elect our directors and our Board of Directors appoints our officers. As of the date of this filing, we have not held an annual meeting. All current directors have been held over until such time the annual meeting is held. Vacancies in our board are filled by the board itself. Set forth below are brief descriptions of the recent employment and business experience of our executive officers and directors.

Keith Berman has served as President, Chief Financial Officer, Secretary, Treasurer and Director of the Company since January of 2003. For over the past 15 years, Mr. Berman has been involved in the development of healthcare software including Intranet and Internet systems. From July 1999 to present, Mr. Berman has held the position of President, founder and director of Caredecision.net, Inc. a private company engaged in e-health technology development. From March 2001 through June 2002 Mr. Berman also held the Position of President and Director or Medicius, Inc. From January 1996 to June 1999 Mr. Berman was the President and founder of Cymedix, the operating division of Medix Resources, Inc., now Ramp Corp. (RCO). Cymedix was a pioneer company in what was then known as i-health (Internet healthcare) now the e-health industry. Mr. Berman's professional background provides the Company with business management experience and an in depth knowledge of our industry. Mr. Berman received a BA in 1975 and an MBA in 1977, from Indiana University.

Robert Jagunich has served as a Director of the Company since January of 2003. Mr. Jagunich has 27 years of experience in the medical systems and device industry. From August 1992 to present, he has held the position of President at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. He also provides consulting services to companies such as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. From April 1996 to December 1997 Mr. Jagunich acted as a director of Cymedix Corporation, the operating entity of Medix Resources, Inc., and later, Ramp Corp. (formerly AMEX:RCO). Mr. Jagunich's professional focus on medical devices as well as the professional relationships he has developed throughout his career provides the Company with opportunities to expand current markets and utilize additional product resources not previously available. He received his BS in 1969, and his MS and MBA in 1971, from the University of Michigan.

William Lyons has served as a Director of the company from January 2003 through October 2003 and most recently from January 2010 to the present time. Mr. Lyons is currently President and COO of Beacon Medical, Inc. a company specializing in the development, manufacturing, marketing and distribution of medical devices and instruments targeted primarily to the Plastic Surgery medical specialty. Prior to that, Mr. Lyons was co-founder, Executive Vice President and Director of BioElectronics Corporation. Mr. Lyons has successfully performed as President or Executive Vice President of several healthcare start-up communication technology and digital integration corporations. Mr. Lyons has also served in various executive positions for several fortune 500 companies such as American Sterilizer Company, Everest and Jennings and Allscrips. Mr. Lyon's professional experience with start-up companies in the medical technology industry as well as his knowledge in finance provide the Company with guidance in capital formation and sustainability. He holds an MBA in finance and a BA in Philosophy.

Mr. Berman, officer and director, works full-time for the company. Messrs. Jagunich and Lyons attend meetings of the board of directors when held and provides 20% and 25% respectively of their business time in professional capacities to the Company.

The following table sets forth information the remuneration of our Principal Executive officer for the years ended December 31, 2015, 2014 and 2013:

Summary Compensation Table

Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards	Option Awards	Non-Equity	Nonqualified Deferred	All Other	Total ($)

				($)	($)	Incentive Plan Compensation ($)	Compensation Earnings ($)	Compensation ($)	
Keith Berman,	2014	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-
CFO and PEO	2015	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-
	2016	$ -0-	-0-	$ -0-	-0-	-0-	-0-	-0-	$ -0-

Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August 2006. During the fiscal years ended December 31, 2014 and 2015. Through March 31, 2016 Mr. Berman has received no cash compensation. Mr. Berman has not received any form of compensation as a result of our limited cash flow; Mr. Berman has agreed to accept stock awards as his compensation until such time the Company has the necessary resources available to provide a traditional compensation plan.

Name of Beneficial Owner, Officer or Director	Number of Shares	Percent of Outstanding Shares of Common Stock(
Keith Berman, Chief Financial Officer and Director	480,103	<1.0%
Robert Jagunich, Director	929,301	1.4%
William Lyons	-	-
Directors and Officers as a Group	1,409,404	2.2%
Barbara Asbell 7061 Los Coyotes Camarillo, CA 93012	1,162,590	1.8%
Directors, Officers and Beneficial Owners as a Group	2,571,994	4.0%

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

   None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Name: Thomas C. Cook
Firm: Law Offices of Thomas C. Cook
Address 1: 8250 W. Charleston Blvd. Ste. 120
Address 2: Las Vegas, NV 89117
Phone: (702) 242-0099
Email: tccesq@aol.com

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

CERTIFICATION

I, Keith Berman, certify that;

(1) I have reviewed this disclosure statement and Annual Reports for the periods ended March 31, 2016 and March 31, 2015.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) revaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 16, 2016

/s/Keith Berman
Keith Berman
Principal Executive Officer and a Director
(Principal Financial Officer)

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Keith Berman, the Principal Executive Officer of Decision Diagnostics Corp., and Principal Financial Officer of Decision Diagnostics Corp.,., hereby certifies, that, to his knowledge, the Annual Report of Decision Diagnostics Corp. for the periods ended March 31, 2016, and March 31, 2015, fully complies with the requirements of this Disclosure Statement and of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Annual Report and this disclosure fairly presents in all material respects the financial condition and results of operations of Decision Diagnostics Corp.

Date: May 16, 2016

/s/Keith Berman
Keith Berman
Principal Executive Officer and

Principal Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to Decision Diagnostics Corp. and will be retained by Decision Diagnostics Corp. and furnished to any regulatory body or OTC Markets, Inc. or their staff upon request.